CN Patent

CN111615558A — 用于调节erc1表达的寡核苷酸

Assigned to Roche Innovation Center Copenhagen AS · Expires 2020-09-01 · 6y expired

What this patent protects

本发明涉及能够减少靶细胞中ERC1表达的反义寡核苷酸。该寡核苷酸与ERC1前‑mRNA杂交。本发明还涉及寡核苷酸的缀合物和药物组合物以及使用反义寡核苷酸治疗与ERC1过表达相关的疾病，例如癌症或登革热病毒感染的方法。

USPTO Abstract

本发明涉及能够减少靶细胞中ERC1表达的反义寡核苷酸。该寡核苷酸与ERC1前‑mRNA杂交。本发明还涉及寡核苷酸的缀合物和药物组合物以及使用反义寡核苷酸治疗与ERC1过表达相关的疾病，例如癌症或登革热病毒感染的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111615558A
Jurisdiction
CN
Classification
—
Expires
2020-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Roche Innovation Center Copenhagen AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.